Companion diagnostics in fields like oncology are well-known, but it’s their potential impact on psychiatry that is gaining attention and has the potential to shape the future of the industry.

First companion diagnostic claim for Illumina's TruSight™ Oncology Comprehensive (EU) test enables targeted therapy with Bayer's VITRAKVI® (larotrectinib) for patients with NTRK fusion cancer SAN ...

Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy. At Illumina’s Genomics Forum conference this fall, former ...

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a collaboration with Boehringer Ingelheim to pursue the regulatory ...

Companion diagnostics (CDx) are vital to precision oncology, enabling clinicians to match patients with therapies based on personalized factors such as biomarker profiles. However, traditional CDx ...

TUCSON, Ariz., Feb. 9, 2023 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it has expanded its collaboration with Janssen Biotech Inc. (Janssen) to create companion ...

Zelboraf is approved for metastatic tumors that express the BRAF V600E mutation. FDA approved Roche’s Zelboraf (vemurafenib) to treat patients with late-stage or unresectable melanoma alongside a ...

The growth of the companion diagnostics market is largely driven by the sharp worldwide rise in cancer incidence. Increasing awareness of precision medicine among patients, along with manufacturers' ...

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that its PD-L1 IHC 22C3 pharmDx assay is now labelled for use in TNBC in the European Union. PD-L1 expression ...

Prevalence of somatic PIK3CA mutations in hormone receptor-positive metastatic breast cancer: The Indian experience. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This abstract ...

ExosomeDx, together with its parent company Bio-Techne, combines expertise in exosome technologies with experience in the non-invasive liquid biopsy market to create solutions for companion diagnostic ...